Section Arrow
MTVA.NASDAQ
- MetaVia Inc.
Quotes are at least 15-min delayed:2026/07/15 06:07 EDT
Pre Market
Last
 1.93
0 (0.00%)
Bid
1.82
Ask
1.94
High 1.94 
Low 1.7503 
Volume 28.07K 
Regular Hours (Closed)
Last
 1.93
-0.06 (-3.02%)
Day High 
2.04 
Prev. Close
1.99 
1-M High
2.6098 
Volume 
482.58K 
Bid
1.82
Ask
1.94
Day Low
1.8401 
Open
1.92 
1-M Low
1.38 
Market Cap 
10.28M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.6 
20-SMA 1.6 
50-SMA 1.86 
52-W High 19.0289 
52-W Low 0.9661 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.21/-2.41
Enterprise Value
10.42M
Balance Sheet
Book Value Per Share
1.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NXTCNextCure Inc6.58+4.4+201.83%-- 
Pre Market 4.9 -1.68 -25.53%
AEONAEON Biopharma0.357+0.0349+10.84%-- 
Pre Market 0.2939 -0.0631 -17.68%
GOSSGossamer Bio0.1401-0.004-2.78%-- 
Pre Market 0.1419 +0.0018 +1.28%
RXRXRecursion Pharmaceuticals3.34+0.04+1.21%-- 
Pre Market 3.37 +0.03 +0.90%
ENSCEnsysce Biosciences0.2925+0.017+6.17%-- 
Pre Market 0.2721 -0.0204 -6.97%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.